Munich - Delayed Quote EUR

NovoCure Ltd (038.MU)

16.14

0.00

(0.00%)

As of 8:04:20 AM GMT+2. Market Open.

Why NovoCure Stock Skyrocketed This Week

Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. The medical technology company reported solid first-quarter results.

Motley Fool 3 days ago

NVCR
Why NovoCure Stock Leaped 4% Higher Today

Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million.

Motley Fool 4 days ago

NVCR
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 4 days ago

NVCR
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 34.04% and 5.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 days ago

NVCR
NovoCure: Q1 Earnings Snapshot

ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $34.3 million in its first quarter. On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 31 cents.

Associated Press Finance 4 days ago

NVCR
Novocure Reports First Quarter 2025 Financial Results

BAAR, Switzerland, April 24, 2025--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

Business Wire 4 days ago

NVCR
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

BAAR, Switzerland, April 23, 2025--Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago.

Business Wire 5 days ago

NVCR
Novocure’s device for metastatic NSCLC treatment gains CE Mark

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Medical Device Network 5 days ago

NVCR
Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index rising 1.5% a

PREMIUM
MT Newswires 6 days ago

BHC

NVCR
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 days ago

EXEL

NVCR
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

BAAR, Switzerland, April 22, 2025--Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.

Business Wire 6 days ago

NVCR
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 11 days ago

NVCR
Why NovoCure Stock Was Withering on Wednesday

Cancer-focused biotech NovoCure (NASDAQ: NVCR) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it. The analyst behind the reduction was Wedbush's David Nierengarten, who now believes NovoCure is worth $27 per share. As the change isn't significant Nierengarten, maintained his neutral recommendation on the company.

Motley Fool 12 days ago

NVCR
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 18 days ago

TECH

NVCR
Novocure to Report First Quarter 2025 Financial Results

BAAR, Switzerland, April 01, 2025--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company’s financial results for the three-month quarter that ended March 31, 2025.

Business Wire 27 days ago

NVCR
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

BAAR, Switzerland, March 04, 2025--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event.

Business Wire last month

NVCR
NovoCure Full Year 2024 Earnings: EPS Misses Expectations

NovoCure ( NASDAQ:NVCR ) Full Year 2024 Results Key Financial Results Revenue: US$605.2m (up 19% from FY 2023). Net...

Simply Wall St. last month

NVCR
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...

NovoCure Ltd (NVCR) reports a 21% revenue increase in Q4 2024, driven by FDA approvals and successful trials, despite facing a net loss and rising expenses.

GuruFocus.com last month

NVCR
NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2024.

Motley Fool last month

NVCR
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

NVCR

Performance Overview

Return	038.MU	S&P 500 (^GSPC)
YTD	-45.33%	-6.00%
1-Year	+38.66%	+8.06%
3-Year	-78.25%	+33.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NovoCure Ltd (038.MU)

Why NovoCure Stock Skyrocketed This Week

Why NovoCure Stock Leaped 4% Higher Today

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure: Q1 Earnings Snapshot

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure’s device for metastatic NSCLC treatment gains CE Mark

Sector Update: Health Care Stocks Rise Late Afternoon

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Why NovoCure Stock Was Withering on Wednesday

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Novocure to Report First Quarter 2025 Financial Results

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Full Year 2024 Earnings: EPS Misses Expectations

NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

Performance Overview